MedTrace Logo

Positron Emission Mammography With Fluorothymidine (FLT) to Evaluate Treatment Response to Chemotherapy in Breast Cancer

NCT00934401 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2016-07-11

No results posted yet for this study

Summary

Positron Emission Tomography Imaging with 3-Deoxy-3'-\[18F\]Fluorothymidine (FLT) can selectively identify proliferating and non-proliferating tissues, including tumors. FLT uptake in the tumor is an indirect marker of DNA synthesis activity, which is a target of chemotherapy. Our hypothesis is that early change in FLT uptake in tumor with chemotherapy will predict pathological response to neoadjuvant therapy in breast cancer. Tumor uptake of FLT will be imaged and measured with positron emission mammography (PEM), a PET scanner optimized for breast imaging with a significantly improved resolution compared to conventional whole-body PET imaging systems.

Conditions

  • Breast Neoplasms

Sponsors & Collaborators

  • University of Iowa

    lead OTHER

Principal Investigators

  • Yusuf Menda, M.D. · The University of Iowa Hospitals & Clinics

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00934401 on ClinicalTrials.gov